Clearside Biomedical (CLSD) Expected to Announce Quarterly Earnings on Tuesday

Clearside Biomedical (NASDAQ:CLSD) is projected to announce its earnings results before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $0.29 million for the quarter.

Clearside Biomedical Trading Down 4.9 %

CLSD stock opened at $0.93 on Monday. The firm has a market capitalization of $70.37 million, a PE ratio of -2.06 and a beta of 2.10. Clearside Biomedical has a one year low of $0.77 and a one year high of $2.12. The firm has a 50-day moving average of $0.96 and a two-hundred day moving average of $1.06.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CLSD. StockNews.com upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Clearside Biomedical in a research report on Thursday. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Clearside Biomedical in a research report on Thursday. Finally, Chardan Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of Clearside Biomedical in a research report on Friday, November 15th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Clearside Biomedical has an average rating of “Moderate Buy” and an average price target of $5.33.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.